Research Paper Volume 13, Issue 1 pp 933—943

IRF-1 contributes to the pathological phenotype of VSMCs during atherogenesis by increasing CCL19 transcription

IRF-1 transcriptionally activated CCL19 expression in VSMCS. (A) Predictive motif of IRF-1 binding to gene promoter. (B) The schematic diagram of sequence complementarity between the IRF-1 and CCL19 predicted on JASPAR datasets. (C) Chromatin immunoprecipitation (ChIP) assay revealed an association between IRF-1 and CCL19 in VSMCS; IgG served as a negative control; n = 3. (D) cells were transfected mut-CCL19/CCL19 with the presence or absence of IRF-1, luciferase activity was measured by dual-luciferase reporter assay system. n=5. (E) qRT-PCR detected CCL19 mRNA level after overexpression of IRF-1. n=5. (F) Detection of IRF-1 expression in peripheral blood of patients by ELISA.n=32. (G) Pearson correlation analysis showed a positive correlation between IRF-1 and CCL19 in peripheral blood. R=0.3933, P

Figure 4. IRF-1 transcriptionally activated CCL19 expression in VSMCS. (A) Predictive motif of IRF-1 binding to gene promoter. (B) The schematic diagram of sequence complementarity between the IRF-1 and CCL19 predicted on JASPAR datasets. (C) Chromatin immunoprecipitation (ChIP) assay revealed an association between IRF-1 and CCL19 in VSMCS; IgG served as a negative control; n = 3. (D) cells were transfected mut-CCL19/CCL19 with the presence or absence of IRF-1, luciferase activity was measured by dual-luciferase reporter assay system. n=5. (E) qRT-PCR detected CCL19 mRNA level after overexpression of IRF-1. n=5. (F) Detection of IRF-1 expression in peripheral blood of patients by ELISA.n=32. (G) Pearson correlation analysis showed a positive correlation between IRF-1 and CCL19 in peripheral blood. R=0.3933, P<0.01. *P<0.05; **P<0.01.